Previous close | 3.0500 |
Open | 3.0500 |
Bid | 2.4500 |
Ask | 6.1000 |
Strike | 140.00 |
Expiry date | 2023-05-19 |
Day's range | 3.0500 - 3.0500 |
Contract range | N/A |
Volume | |
Open interest | 44 |
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22. Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the Investor R
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.
Repligen ( NASDAQ:RGEN ) Full Year 2022 Results Key Financial Results Revenue: US$801.5m (up 20% from FY 2021). Net...